Primary Immunodeficiency Diseases research hub

Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)

This study is looking at a new treatment called TAK-881 for people with primary immunodeficiency diseases (PIDD). Researchers want to understand how the body uses TAK-881, if it's safe, and if it helps prevent infections. It compares TAK-881 to an existing treatment, HyQvia.